PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-3.66%
Negative net income growth while AGEN stands at 4.33%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
13.04%
Less D&A growth vs. AGEN's 35.63%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
100.00%
Deferred tax of 100.00% while AGEN is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
1.43%
Less SBC growth vs. AGEN's 28.79%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-401.62%
Both reduce yoy usage, with AGEN at -70.26%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both negative yoy AP, with AGEN at -60.58%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-97.99%
Both reduce yoy usage, with AGEN at -66.61%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-100.00%
Both negative yoy, with AGEN at -61.90%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-93.84%
Both yoy CFO lines are negative, with AGEN at -23.63%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-375.00%
Negative yoy CapEx while AGEN is 87.16%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-375.00%
Both yoy lines negative, with AGEN at -79.99%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-84.27%
Negative yoy issuance while AGEN is 152.83%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.